Nonlinear dose-response of mind-body exercise in older adults with mild cognitive impairment: A systematic review and meta-analysis.

PLoS OneSep 25, 2026 (epub)
Clinical ResearchGeriatrics

Yan-Fang Peng, Xi Chen, Guo-Qing Zhu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the dose-response relationship of mind-body exercise on cognitive function in older adults with mild cognitive impairment (MCI). Analyzing 27 randomized controlled trials with 2034 participants, the study found moderate-certainty evidence of improved global cognition (Hedges' g: 0.67) and processing speed (0.45). A U-shaped dose-response was identified, with 240 minutes per week as a significant threshold.

Key findings

  • Global cognition improved with a Hedges' g of 0.67, indicating a moderate effect.
  • Processing speed showed a Hedges' g of 0.45, suggesting a positive impact.
  • A U-shaped dose-response for global cognition indicated 240 min/week as a significant threshold.
  • Significant benefits for global cognition required at least 11 weeks of intervention.

Why it matters

Understanding the specific dose-response relationships of mind-body exercise can help clinicians tailor interventions for older adults with MCI, potentially enhancing cognitive outcomes and overall quality of life.

Source

PubMed · PMID 42789586

Published in PLoS One. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.